Participation in clinical trials is one way that patients who are affected by ILC can help advance the understanding of lobular breast disease. These are especially important to help determine how current standards of breast cancer treatment might be improved to better address the unique needs of those with ILC.

The following 3 new ILC clinical trials are open online, to read more about eligibility requirements and how to apply click the links below.

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

LOCATION: USA

This pilot study evaluates a novel PET imaging agent (PYLARIFY, piflufolastat F18) in patients with suspected or confirmed metastatic cancer, including invasive lobular breast cancer. Participants will undergo PET/CT imaging to assess how accurately this approach detects metastatic lesions compared to standard imaging and biopsy results. The study aims to determine whether this imaging method can better identify the extent of disease. 

Improving Detection and Outcomes in Patients With Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAPI PET Imaging

LOCATION: USA 

This pilot imaging study compares a novel PET scan (FAPI PET/CT) with the current standard (FDG PET/CT) in patients with metastatic invasive lobular breast cancer. Participants will undergo both scans within a short time period, allowing researchers to directly evaluate differences in lesion detection, tumor visibility, and clinical usefulness, including whether the new imaging approach may better inform treatment decisions. 

8F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer 

LOCATION: ITALY 

This study aims to evaluate whether 18F-fluoroestradiol (FES) PET/MRI, an imaging approach that uses a radiolabeled form of estrogen, can enhance disease staging and inform treatment planning in patients with Luminal A and ER-positive lobular breast cancer eligible for primary surgical intervention. Participants will undergo additional FES-PET/MRI in addition to standard imaging to assess disease extent and to characterize imaging features potentially associated with tumor biology prior to surgery.